Tsuyoshi Fukuda, PhD

Associate Professor, UC Department of Pediatrics

Phone 513-803-0428

Fax 513-636-0168

Email tsuyoshi.fukuda@cchmc.org

Clinical pharmacology (pharmacogenetics, pharmacokinetics and pharmacodynamics)

Dr. Fukuda received his pharmacy degree and PhD in pharmaceutical science from Osaka University, Japan. He received postdoctoral training in the Division of Clinical Pharmacology and Pharmacogenomics (Prof. J. Azuma, MD) and served as an assistant professor at Osaka University, Graduate School of Pharmaceutical Sciences. He joined the Division of Clinical Pharmacology (Prof. Alexander A Vinks, PharmD, PhD) at Cincinnati Children's Hospital Medical Center in 2007. He spent over 15 years in the field of clinical pharmacology while engaged in pharmacogenetic (PG) and pharmacokinetic-pharmacodynamic (PK/PD) research. His current research interests include the clinical application of integrated PK/PD/PG modeling and simulation and physiologically based pharmacokinetic (PBPK) analysis with developmental pharmacology, focusing on improving our understanding of inter-patient differences in drug response and developing individualized dosing strategies in pediatric patients. 

Dr. Fukuda’s efforts have resulted in over 50 peer-reviewed publications with project members that include master's and PhD students, research fellows, clinical fellows, pharmacists, physicians, and private sector R & D staff.

BS: Osaka University, School of Pharmacy, Osaka, Japan, 1995.

Pharmacist: Japan, 1995.

MS: Osaka University, Osaka, Japan,1997.

PhD: Osaka University, Osaka, Japan, 2000.

Certification: Clinical Pharmacology (Pharmacist), 2003 (Japanese Society of Clinical Pharmacology), 2008 renewed.

Mizuno T, Fukuda T, Masuda S, Uemoto S, Matsubara K, Inui KI, Vinks AA. Developmental trajectory of intestinal MDR1/ABCB1 expression in children. Br J Clin Pharmacol. 2013 Jul 23. [Epub ahead of print].

Emoto C, Fukuda T, Cox S, Christians U, Vinks AA. Development of a physiologically-based pharmacokinetic model for sirolimus: predicting bioavailability based on intestinal CYP3A content. CPT Pharmacometrics Syst Pharmacol. 2013 Jul 24;2:e59.

Fukuda T, Chidambaran V, Mizuno T, Venkatasubramanian R, Ngamprasertwong P, Olbrecht V, Esslinger HR., Vinks AA, Sadhasivam S. Organic Cation Transporter 1 Genetic Variants influence the pharmacokinetics of Morphine in Children. Pharmacogenomics. 2013 Jul;14(10):1141-51.

Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D. Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med. 2013 Jul;39(7):1247-52.

Shimamoto Y, Fukuda T, Tominari S, Fukumoto K, Ueno K, Dong M, Tanaka K, Shirasaka T, Komori K. Decreased vancomycin clearance in patients with congestive heart failure. Eur J Clin Pharmacol. 2013 Mar;69(3):449-57.

Fukuda T, Goebel J, Cox S, Maseck D, Zhang K, Sherbotie JR, Ellis EN, James LP, Ward RM, Vinks AA. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients. Ther Drug Monit. 2012 Dec;34(6):671-9.

Hooper DK, Fukuda T, Gardiner R, Logan B, Roy-Chaudhury A, Kirby CL, Vinks AA, Goebel J. Risk of Tacrolimus Toxicity in CYP3A5 Non-Expressors Treated with Intravenous Nicardipine After Kidney Transplantation. Transplantation. 2012 Apr 27;93(8):806-12.

Fukuda T, Brunner HI, Sagcal-Gironella AC, Vinks AA. Non-steroidal Anti-Inflammatory Drugs may reduce Enterohepatic Recirculation of Mycophenolic Acid in Patients with Childhood-onset Systemic Lupus Erythematosus. Ther Drug Monit. 2011 Oct;33(5):658-62.

Sagcal-Gironella AC, Fukuda T, Wiers T,  Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner HI. Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid and Their Relation to Response to Therapy of Childhood-onset Systemic Lupus Erythematosus. Seminars in Arthritis and Rheumatism. 2011 Feb;40(4):307-13.

Fukuda T, Goebel J, Thøgersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA. Inosine Monophosphate Dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of Mycophenolic Acid effects in Pediatric Kidney Transplant RecipientsJ Clin Pharmacol. 2011 Mar;51(3):309-20.